VinaR - Repository of the Vinča Nuclear Institute
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   Vinar
  • Vinča
  • Radovi istraživača
  • View Item
  •   Vinar
  • Vinča
  • Radovi istraživača
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Recent advances on smart glycoconjugate vaccines in infections and cancer

Thumbnail
Main article [PDF] (8.766Mb)
Authors
Anderluh, Marko
Berti, Francesco
Bzducha-Wróbel, Anna
Chiodo, Fabrizio
Colombo, Cinzia
Compostella, Federica
Durlik, Katarzyna
Ferhati, Xhenti
Holmdahl, Rikard
Jovanović, Dragana J.
Kaca, Wieslaw
Lay, Luigi
Marinovic-Cincovic, Milena
Marradi, Marco
Ozil, Musa
Polito, Laura
Reina, Josè Juan
Reis, Celso A.
Sackstein, Robert
Silipo, Alba
Švajger, Urban
Vaněk, Ondřej
Yamamoto, Fumiichiro
Richichi, Barbara
van Vliet, Sandra J.
Article (Published version)
Metadata
Show full item record
Abstract
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally s...erve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.

Keywords:
cancer / glycosylation / immune system / infection / vaccination
Source:
The FEBS Journal
Funding / projects:
  • COST [CA18103]
  • Ministry of Education, Youth & Sports - Czech Republic [CA18103, LTC20078]

DOI: 10.1111/febs.15909

ISSN: 1742-4658

PubMed: 33934527

WoS: 000656594400001

Scopus: 2-s2.0-85107309134
[ Google Scholar ]
15
4
URI
https://vinar.vin.bg.ac.rs/handle/123456789/9834
Collections
  • Radovi istraživača
Institution/Community
Vinča
TY  - JOUR
AU  - Anderluh, Marko
AU  - Berti, Francesco
AU  - Bzducha-Wróbel, Anna
AU  - Chiodo, Fabrizio
AU  - Colombo, Cinzia
AU  - Compostella, Federica
AU  - Durlik, Katarzyna
AU  - Ferhati, Xhenti
AU  - Holmdahl, Rikard
AU  - Jovanović, Dragana J.
AU  - Kaca, Wieslaw
AU  - Lay, Luigi
AU  - Marinovic-Cincovic, Milena
AU  - Marradi, Marco
AU  - Ozil, Musa
AU  - Polito, Laura
AU  - Reina, Josè Juan
AU  - Reis, Celso A.
AU  - Sackstein, Robert
AU  - Silipo, Alba
AU  - Švajger, Urban
AU  - Vaněk, Ondřej
AU  - Yamamoto, Fumiichiro
AU  - Richichi, Barbara
AU  - van Vliet, Sandra J.
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9834
AB  - Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
T2  - The FEBS Journal
T1  - Recent advances on smart glycoconjugate vaccines in infections and cancer
DO  - 10.1111/febs.15909
ER  - 
@article{
author = "Anderluh, Marko and Berti, Francesco and Bzducha-Wróbel, Anna and Chiodo, Fabrizio and Colombo, Cinzia and Compostella, Federica and Durlik, Katarzyna and Ferhati, Xhenti and Holmdahl, Rikard and Jovanović, Dragana J. and Kaca, Wieslaw and Lay, Luigi and Marinovic-Cincovic, Milena and Marradi, Marco and Ozil, Musa and Polito, Laura and Reina, Josè Juan and Reis, Celso A. and Sackstein, Robert and Silipo, Alba and Švajger, Urban and Vaněk, Ondřej and Yamamoto, Fumiichiro and Richichi, Barbara and van Vliet, Sandra J.",
abstract = "Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.",
journal = "The FEBS Journal",
title = "Recent advances on smart glycoconjugate vaccines in infections and cancer",
doi = "10.1111/febs.15909"
}
Anderluh, M., Berti, F., Bzducha-Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., Kaca, W., Lay, L., Marinovic-Cincovic, M., Marradi, M., Ozil, M., Polito, L., Reina, J. J., Reis, C. A., Sackstein, R., Silipo, A., Švajger, U., Vaněk, O., Yamamoto, F., Richichi, B.,& van Vliet, S. J..Recent advances on smart glycoconjugate vaccines in infections and cancer. in The FEBS Journal.
https://doi.org/10.1111/febs.15909
Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanović DJ, Kaca W, Lay L, Marinovic-Cincovic M, Marradi M, Ozil M, Polito L, Reina JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, van Vliet SJ. Recent advances on smart glycoconjugate vaccines in infections and cancer. in The FEBS Journal..
doi:10.1111/febs.15909 .
Anderluh, Marko, Berti, Francesco, Bzducha-Wróbel, Anna, Chiodo, Fabrizio, Colombo, Cinzia, Compostella, Federica, Durlik, Katarzyna, Ferhati, Xhenti, Holmdahl, Rikard, Jovanović, Dragana J., Kaca, Wieslaw, Lay, Luigi, Marinovic-Cincovic, Milena, Marradi, Marco, Ozil, Musa, Polito, Laura, Reina, Josè Juan, Reis, Celso A., Sackstein, Robert, Silipo, Alba, Švajger, Urban, Vaněk, Ondřej, Yamamoto, Fumiichiro, Richichi, Barbara, van Vliet, Sandra J., "Recent advances on smart glycoconjugate vaccines in infections and cancer" in The FEBS Journal,
https://doi.org/10.1111/febs.15909 . .

DSpace software copyright © 2002-2015  DuraSpace
About the VinaR Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About the VinaR Repository | Send Feedback

OpenAIRERCUB